TMHS 517: The FDA’s Vaccine Advisory Meeting & Another Blockbuster Drug Recall

1:22:37
 
Share
 

Manage episode 303378397 series 60566
By Shawn Stevenson. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Right now, there’s a lot of opinions and discrepancies surrounding the idea of a COVID-19 booster shot. In fact, the FDA’s approval varies slightly from the CDC recommendations. It’s no wonder that there are a multitude of varying ideas on this topic.

On today’s show, we’re going behind the scenes of the FDA booster approval and discussing the pertinent data on mRNA studies, the pharmaceutical industry at large, and the COVID-19 vaccine. You’re going to learn the specifics of the COVID-19 vaccine booster trials, how the FDA operates, and why some key information being reported is not quite what it seems.

No matter where you stand on this issue, I hope you can approach this episode with an open mind, logic, and reason. I hope this episode gives you insight into clinical trials, government agencies, and how to take a broader look at what’s happening in our current events. So click play, listen in, and enjoy the show!

In this episode you’ll discover:

  • How protocol was broken during the initial mRNA trials.
  • What happens in a study when you lose the control group.
  • Which pharmaceutical company paid the largest healthcare fraud settlement.
  • How often unsafe drugs are typically prescribed before being recalled.
  • The number of yearly hospitalizations that are caused by properly prescribed drugs.
  • How many serious adverse drug reactions occur in the US every year.
  • What FDA user fees are and how they work.
  • The connection between the FDA and pharmaceutical companies.
  • How the news media and the government are intertwined.
  • The amount of test subjects evolved in the COVID-19 vaccine booster trials.
  • What the FDA advisory committee final vote was for individuals 16 years and older.
  • The difference between relative risk reduction and absolute risk reduction.
  • Why breakthrough cases were likely underreported.
  • Some of the adverse effects reported from the COVID-19 vaccine.
  • What you should know about the VAERS database.

Items mentioned in this episode include:

Join TMHS Facebook community - Model Nation

Be sure you are subscribed to this podcast to automatically receive your episodes:

*Download Transcript

535 episodes